

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. - 8. (Canceled)

9. (Currently Amended) A method of monitoring the concentration of an analyte in a host or portion thereof over a given time period using a monitoring device, said method comprising:

(a) making a first analyte concentration measurement in said host or portion thereof ~~at a first point in said time period~~ using a first single use analyte concentration measurement ~~means~~ arrangement;

(b) making a second analyte concentration measurement in said host or portion thereof ~~at a second point in said time period~~ using a second single use analyte concentration measurement ~~means~~ arrangement; and

(c) making one or more additional analyte concentration measurements during said time period using one or more additional single use analyte concentration measurement ~~means~~ arrangement;

wherein said analyte concentration measurements of (a) and (b) are automatically made according to a selected ~~scheduling mode~~ schedule contained in the monitoring device to monitor the concentration of said analyte in said host or portion thereof over said given time period.

10. (Previously Presented) The method according to claim 9, wherein said host or portion thereof is interstitial fluid.

11. (Currently Amended) The method according to claim 10, wherein said single use analyte concentration measurement ~~means~~ arrangements ~~is~~ are an interstitial fluid analyte measurement ~~means~~ arrangements.

12. (Currently Amended) The method according to claim 11, wherein said interstitial fluid analyte measurement ~~means~~ arrangements ~~makes-an~~ make in situ analyte concentration measurement ~~measurements~~.

13. (Currently Amended) The method according to claim 11, wherein said interstitial fluid analyte measurement ~~means~~ arrangements ~~makes-an~~ make ex vivo analyte concentration measurement ~~measurements~~.

14. (Currently Amended) The method according to claim 13, wherein said interstitial fluid analyte concentration measurement ~~means~~ arrangements ~~removes~~ remove interstitial fluid from said host and ~~analyzes~~ analyze said fluid outside of said host.

15. (Currently Amended) The method according to claim 11, wherein said interstitial fluid analyte concentration measurement ~~means~~ arrangements comprise ~~comprises~~ a microneedle.

16. (Previously Presented) The method according to claim 9, wherein said analyte is glucose.

17. (Currently Amended) The method according to claim 9, wherein the selected ~~scheduling mode~~ schedule comprises a predetermined schedule.

18. (Previously Presented) The method according to claim 17, wherein the predetermined schedule comprises measurements taken at fixed time intervals.

19. (Previously Presented) The method according to claim 17, wherein the predetermined schedule comprises measurements taken at fixed times.

20. - 22. (Canceled)

23. (Currently Amended) A method of monitoring the concentration of glucose in interstitial fluid of a host over a given time period using a monitoring device, said method comprising:

(a) making a first interstitial fluid glucose concentration measurement at ~~a first point in said time period~~ using a first single use interstitial fluid glucose concentration measurement ~~means~~ arrangement;

(b) making a second interstitial fluid glucose concentration measurement ~~at a second point in said time period~~ using a second single use interstitial fluid glucose concentration measurement ~~means~~ arrangement; and

(c) making one or more additional interstitial fluid glucose concentration measurements during said time period using one or more additional single use interstitial fluid glucose concentration measurement ~~means~~ arrangement;

wherein said interstitial fluid glucose concentration measurements (a) and (b) are automatically made according to a predetermined schedule contained in the device to monitor the concentration of interstitial fluid glucose over said given time period.

24. (Currently Amended) The method according to claim 23, wherein said interstitial fluid glucose measurement ~~means~~ arrangements make ~~makes an in situ measurement~~ measurements.

25. (Currently Amended) The method according to claim 24, wherein said interstitial fluid glucose measurement ~~means~~ arrangements make ~~makes an ex vivo measurement~~ measurements.

26. (Currently Amended) The method according to claim 25, wherein said interstitial fluid glucose concentration measurement ~~means~~ removes arrangements remove interstitial fluid from said host and ~~analyzes~~ analyze said fluid outside of said host.

27. (Currently Amended) The method according to claim 23, wherein said interstitial fluid glucose concentration measurement ~~means~~ arrangements comprise ~~comprises~~ a microneedle.

28. - 29. (Canceled)

30. (Currently Amended) A monitoring device for use in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said device comprising:

(a) at least a first and a second single use analyte concentration measurement ~~means~~ arrangements;

(b) a timing device ~~comprising a predetermined timetable~~; and

(c) an activation ~~means~~ mechanism for ~~selectively~~ automatically activating said first and second analyte concentration measurement ~~means~~ arrangements according to the a predetermined schedule contained in the monitoring device.

31. (Canceled)

32. (Currently Amended) The device according to claim 30, wherein said analyte concentration measurement ~~means~~ arrangements are interstitial fluid analyte concentration measurement ~~means~~ arrangements.

33. (Currently Amended) The device according to claim 32, wherein said interstitial fluid analyte concentration measurement ~~means~~ arrangements are glucose concentration measurement ~~means~~ arrangements.

34. (Currently Amended) The device according to claim 32, wherein said interstitial fluid analyte concentration measurement ~~means~~ arrangements each comprise ~~comprises~~ a microneedle.

35. (Currently Amended) The device according to claim 30, wherein said monitoring device comprises a removable cartridge that comprises said first and second analyte concentration measurement means arrangements.

36. (Currently Amended) A system for use in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said system comprising:

- (a) a removable cartridge comprising at least a first and a second single use analyte concentration measurement means arrangements; and
- (b) a monitoring device into which said cartridge may be inserted, wherein said monitoring device comprises a timing device and ~~a comprising a predetermined schedule,~~ and an activation means mechanism for ~~selectively automatically~~ activating said first and second measurement means arrangements of said cartridge according to ~~the~~ a predetermined schedule contained in the monitoring device.

37. (Canceled)

38. (Currently Amended) The system according to claim 36, wherein said means analyte concentration measurement means arrangements of said cartridge are interstitial fluid analyte concentration measurement means arrangements.

39. (Currently Amended) The system according to claim 38, wherein said interstitial fluid analyte concentration measurement means arrangements ~~is~~ are glucose concentration measurement means arrangements.

40. (Currently Amended) The system according to claim 39, wherein said interstitial fluid analyte concentration measurement means arrangements comprise a microneedle.

41. (Currently Amended) A kit for use in monitoring the concentration of an analyte in a host or portion thereof over a given period of time, said kit comprising: ~~at least one of:~~

(a) a removable cartridge comprising at least a first and a second single use analyte concentration measurement ~~means~~ arrangements; and

(b) a device into which said cartridge may be inserted, wherein said device comprises a timing device ~~comprising a predetermined schedule~~; and an activation ~~means~~ mechanism for selectively automatically activating said first and second measurement means of said cartridge according to ~~the~~ a predetermined schedule contained in the device.

42. (Canceled)

43. (Currently Amended) The kit according to claim 41, wherein said analyte concentration measurement ~~means~~ arrangements of said cartridge are interstitial fluid analyte concentration measurement ~~means~~ arrangements.

44. (Currently Amended) The kit according to claim 43, wherein said interstitial fluid analyte concentration measurement ~~means~~ arrangements are glucose concentration measurement ~~means~~ arrangements.

45. (Currently Amended) The kit according to claim 43, wherein said interstitial fluid analyte concentration measurement ~~means~~ arrangements comprise a microneedle.

46. (Previously Presented) The kit according to claim 41, wherein said kit further comprises a second cartridge.

47. (Previously Presented) The kit according to claim 41, wherein said kit further comprises instructions for using said kit in monitoring the concentration of an analyte over a period of time.

48. - 57. (Canceled)

58. (Currently Amended) A method of monitoring the concentration of an analyte in a host over a given time period using a monitoring device, said method comprising:

(a) making a first analyte concentration measurement ~~at a first point in said time period~~ using a first single use analyte concentration measurement ~~means~~ arrangement;

(b) making a second analyte concentration measurement ~~at a second point in said time period~~ using a second single use analyte concentration measurement ~~means~~ arrangement; and

(c) making one or more additional analyte concentration measurements during said time period using one or more additional single use analyte concentration measurement ~~means~~ arrangement;

wherein said analyte concentration measurements are made automatically according to a predetermined schedule selected from two or more predetermined schedules contained in the device and selected by the user or medical personnel to monitor the concentration of interstitial fluid glucose over said given time period.

59. (Currently Amended) The method according to claim 58, wherein said analyte measurement ~~means makes an~~ arrangements make in situ measurement measurements.

60. (Currently Amended) The method according to claim 59, wherein said analyte measurement ~~means makes an~~ arrangements make ex vivo measurement measurements.

61. (Previously Presented) The method according to claim 58, wherein the measurements are in part triggered according to a timetable programmed by the user or medical personnel.

62. (Currently Amended) The method according to claim 58, wherein said analyte concentration measurement ~~means~~ arrangements ~~comprises~~ comprise a microneedle.

63. - 83. (Canceled)

84. (Currently Amended) The method of claim 9, wherein ~~the method is performed with the assistance of an analyte monitoring device~~, the device comprising a controller that triggers (a) and (b) according to the selected ~~scheduling mode~~ schedule.

85. - 86. (Canceled)

87. (Currently Amended) The method of claim ~~86~~ 23, wherein the device further comprises a controller that triggers (a) and (b) according to the predetermined ~~timetable~~ schedule.

88. (Canceled)